Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs.
We couldn't find any ticker for EPRX. Please check if the ticker was entered correctly—or if it is listed. If not, we don't have any data for that asset at the moment :(
...and much more!